Bao Pharma announced that it has received $100,000,000 in a round of funding led by Shenzhen Oriental Fortune Capital Co., Ltd. on August 25, 2022. The transaction included participation from Finnova Capital, Haitong Innovation Private Fund Management Co., Ltd., Shanghai Sun Rock Capital Management Co., Ltd., Center Laboratories, Inc.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
45.05 TWD | -0.55% | +3.44% | +1.69% |
04-22 | Center Laboratories, Inc. cancelled the transaction announced on June 20, 2023 | CI |
03-19 | Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+1.69% | 952M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 4123 Stock
- News Center Laboratories, Inc.
- Bao Pharma announced that it has received $100 million in funding from Shenzhen Oriental Fortune Capital Co., Ltd., Finnova Capital, Haitong Innovation Private Fund Management Co., Ltd., Shanghai Sun Rock Capital Management Co., Ltd., Center Laboratories, Inc.